Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rare T-cell lymphomas.

Ana Maria Molina1, Steven M Horwitz

  • 1Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cancer Treatment and Research
|February 21, 2008
PubMed
Summary
This summary is machine-generated.

Advances in lymphoma pathology reveal rare subtypes, but clinical data and management strategies are lacking. Further research is needed to define optimal treatment for these aggressive, extranodal lymphoid malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026
Same author

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.

Haematologica·2026
Same author

CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

American journal of hematology·2026
Same author

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Blood·2025
Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026
Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026
Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026
Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026
Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026
Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Lymphoma classification is evolving due to advances in pathologic characterization of lymphoid malignancies.
  • Subdividing heterogeneous diseases has led to an increasing number of distinct subtypes, improving diagnostic accuracy.
  • This detailed classification aids in understanding the molecular mechanisms underlying these disorders.

Purpose of the Study:

  • To highlight the clinical information gap for rare lymphoma subtypes.
  • To discuss the limitations of standard staging for extranodal diseases.
  • To review current and potential management strategies for aggressive, rare lymphomas.

Main Methods:

  • Review of evolving lymphoma classification systems and their impact on subtyping.

Related Experiment Videos

  • Assessment of the utility of standard staging and newer technologies like PET scanning.
  • Evaluation of treatment outcomes for aggressive lymphomas (ETCL, HSTCL, GD-TCL) with chemotherapy and high-dose therapy.

    • Main Results:

    • Clinical information and optimal management strategies for rare lymphoma subtypes remain undefined.
    • Standard staging is less useful for these primarily extranodal diseases.
    • Aggressive lymphomas show limited durable remissions with standard chemotherapy; high-dose therapy shows promise but lacks conclusive data.
    • Biologic therapies, like retinoids for SPTCL, offer durable benefit with less toxicity for some patients.

    Conclusions:

    • Larger patient series are required to better define preferred management approaches for rare lymphoma entities.
    • Continued research into molecular mechanisms and treatment efficacy is crucial.
    • Personalized treatment strategies may be necessary given the heterogeneity of these rare lymphoid malignancies.